This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MUHAMMAD ASWAQ, MD; VICTOR RICHARDS, MD; SHEILA McFADDEN

AMA Arch Surg. 1964;89(3):485-487.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the past few years the immunology of cancer has been the subject of feverish activity and great promise. The long anticipated hope that cancer vaccine will some day rid humanity of the scourge of cancer is just beginning to materialize. Numerous reviews^1-8 on the immunologic aspects of cancer have adequately summarized the accomplishments of many scientists in this field. The purpose of this paper is twofold: first, to report our experiences with autogenous cancer vaccine in terminal cancer patients, and second, to show by passive cutaneous anaphylaxis in guinea pigs the ability of cancer patients to produce humoral antibodies to autologous tumor.

Twenty-one patients formed the subject of this study. All had inoperable cancer with unfavorable prognosis. The tissue for the autogenous vaccine was obtained aseptically at the time of surgery and stored at —4 C. The whole tumor homogenate was prepared by cutting 1 gm of tumor . . . [Full Text PDF of this Article]

Author Affiliations
SAN FRANCISCO

From the Surgical Research Laboratories Presbyterian Medical Center.

Footnotes
Submitted for publication March 12, 1964.

This work was supported by a grant from the Damon Runyon Memorial Fund for Cancer Research, Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?